Skip to main content

Table 1 Data in whole cohort (n = 60) at the time of the most recent liver biopsy

From: Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?

Age at biopsy (yrs)

39.4 ± 8.2

Ethnicity

 

White

24 (40%)

Other European

24 (40%)

Others

12 (20%)

Male

54 (90%)

Weight (kg)

72.3 ± 10.1

   > 75 kg

24 (40%)

Diabetes Mellitus

3 (5%)

Lipoatrophy

5 (8%)

Risk factors for HCV

 

IDU

32 (53%)

Blood transfusion

3 (5%)

Homosexual

19 (32%)

Heterosexual

3 (5%)

Tattoos/fisting

3 (5%)

Unknown

1 (2%)

Alcohol Abuse

18 (30%)

CD4+ (/mm3)

450 (100–1200)

HIV VL (copies/ml)

UD (UD-210,955)

Antiretroviral therapy

 

None

17 (28%)

NRTI only

10 (17%)

HAART only

22 (37%)

Sequential therapy

11 (18%)

HCV VL (IU/ml)*

869,299 (2716–14,975,540)

HCV genotype 1*

30/42 (71%)

HCV disease duration (yrs)

16.4 ± 8.0

Liver Biopsy**

 

Fibrosis stage

2.8 ± 1.7

Fibrosis progression rate/yr

0.21 ± 0.16

(FPR)*

 

Cirrhosis

15 (25%)

Necroinflammatory grade

3.7 ± 1.7

Hepatic steatosis

35 (58%)

  1. *HCV viral load and genotyping unavailable in 16 and 18 patients respectively
  2. *FPR unavailable in 22 patients
  3. ** Data in median (range): fibrosis stage 2 (0–6), necroinflammatory grade 3 (1–9), fibrosis progression rate/yr 0.15 (0–0.67), steatosis grade 1 (0–3)
  4. UD: undetectable
  5. Ethnicity: In Other European the country of origin was as follows: Italy n = 8, Portugal n = 8, Spain n = 5, Germany n = 1, France n = 1 and Venezuela n = 1. Others included Brazil n = 3, Russia n = 3, Yugoslavia n = 3, India n = 1, Iran n = 1 and Libya n = 1